Montelukast%25252525252525252525252525252525252520levocetrizine

# Montelukast and Levocetirizine ## Overview This is a combination therapy frequently used for allergic rhinitis and chronic urticaria. Montelukast is a selective leukotriene receptor antagonist (LTRA), and levocetirizine is a potent, third-generation non-sedating H1-antihistamine. They act synergistically to target different inflammatory pathways in the allergic cascade. ## Primary Indications * Allergic Rhinitis (Seasonal and Perennial) * Chronic Urticaria * *Note: Montelukast is also FDA-indicated for asthma prophylaxis.* ## Adult Dosing * **Montelukast:** 10 mg orally once daily in the evening. * **Levocetirizine:** 5 mg orally once daily in the evening. ## Pediatric Dosing * **6–11 Years:** Montelukast 5 mg (chewable) once daily; Levocetirizine 2.5 mg once daily. * **2–5 Years:** Montelukast 4 mg (granules or chewable) once daily; Levocetirizine 1.25 mg once daily. * **6 Months–23 Months:** Levocetirizine 1.25 mg once daily. *Montelukast is generally not indicated below 6 months.* ## Dose Adjustments * **Renal Impairment (Levocetirizine):** Dose must be reduced in patients with CrCl < 80 mL/min. * CrCl 50–79 mL/min: 2.5 mg daily. * CrCl 30–49 mL/min: 1.25 mg daily. * CrCl < 10 mL/min: Contraindicated (End-stage renal disease/dialysis). * **Hepatic Impairment:** No standard adjustment for Montelukast required; monitor for hepatotoxicity. ## Contraindications * **Hypersensitivity:** Known hypersensitivity to montelukast, levocetirizine, or cetirizine. * **Renal:** Severe renal failure (CrCl < 10 mL/min) for levocetirizine. ## Adverse Effects * **Montelukast:** Neuropsychiatric events (agitation, aggression, depression, sleep disturbances, suicidal ideation), headache, upper respiratory infection, and rare Churg-Strauss syndrome. * **Levocetirizine:** Somnolence (less than first-generation antihistamines, but still common), fatigue, nasopharyngitis, and dry mouth. ## Key Drug Interactions * **CYP2C8/2C9 Inducers (e.g., Rifampin):** May decrease montelukast plasma concentrations. * **CNS Depressants:** Concurrent use with alcohol or other sedatives may potentiate the sedative effects of levocetirizine. * **Ritonavir:** May increase plasma concentrations of both medications. ## Monitoring * Monitor for emergent neuropsychiatric symptoms (mood changes, insomnia, anxiety) while on montelukast. * Monitor renal function in patients with preexisting impairment when dosing levocetirizine. * Assess efficacy and sedation levels, particularly in pediatric patients and elderly populations. ## Clinical Pearls * **FDA Boxed Warning (Montelukast):** The FDA mandates a Boxed Warning regarding serious neuropsychiatric events. Providers should weigh the benefits vs. risks of montelukast, especially for non-asthma conditions like allergic rhinitis where alternatives exist. * **Timing:** Both medications, but particularly the antihistamine component, are generally recommended to be taken in the evening to optimize effectiveness during peak symptom periods and minimize daytime sedation. * **Off-label/Local Protocols:** While common in clinical practice, many health systems have specific prescribing restrictions for montelukast due to its safety profile. Always verify local formulary status. *** **Educational Disclaimer:** This information is for educational purposes only. Drug dosing, contraindications, and interaction profiles can change. Always verify current prescribing information using official, updated clinical databases (e.g., Lexicomp, UpToDate) or the manufacturer’s product label before prescribing or administering medication.